Question · asked by 1 review

Summary of findings: colistimethate dry powder for inhalation (Colobreathe®) vs tobramycin: Survival: number of deaths

Population
adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
Intervention
Summary of findings: colistimethate dry powder for inhalation (Colobreathe®)
Comparison
tobramycin
Outcome
Survival: number of deaths

Summary of findings: colistimethate dry powder for inhalation… showed no clear difference in survival: number of deaths compared with tobramycin (low certainty).

What each review found

Include earlier review versions
FindingEffectStudiesGRADE certainty
Summary of findings: colistimethate dry powder for inhalation (Colobreathe®) vs tobramycin
Survival: number of deaths · children and adults with CF and P aeruginosa infection
Summary of findings: colistimethate dry powder for inhalation… showed no clear difference in survival: number of deaths compared with tobramycin (low certainty).
Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis (2022) · Cochrane Headline outcomes only
RR 0.21 [0.01, 4.32]1 study · 374 participantsLow

Findings are shown side by side, never pooled across reviews.

The reviews

ReviewSearched up toIncluded studiesAMSTAR 2
Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis
2022 · Cochrane Headline outcomes only
Not reportedNot extractedNot assessed
How reviews are matched to this question

Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.